252 related articles for article (PubMed ID: 25418344)
1. Paclitaxel-eluting stents for the treatment of femoropopliteal arterial stenoses: focus on the Zilver PTX drug-eluting peripheral stent.
Moukarbel GV; Burket MW
Expert Rev Med Devices; 2015 Mar; 12(2):157-62. PubMed ID: 25418344
[TBL] [Abstract][Full Text] [Related]
2. Bare metal stent versus paclitaxel eluting stent for intermediate length femoropopliteal arterial lesions (BATTLE trial): study protocol for a randomized controlled trial.
Gouëffic Y; Kaladji A; Guyomarch B; Montagne C; Fairier D; Gestin S; Riche VP; Vent PA; Chaillou P; Costargent A; Patra P
Trials; 2014 Oct; 15():423. PubMed ID: 25359394
[TBL] [Abstract][Full Text] [Related]
3. Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Dake MD; Ansel GM; Jaff MR; Ohki T; Saxon RR; Smouse HB; Machan LS; Snyder SA; O'Leary EE; Ragheb AO; Zeller T;
Circulation; 2016 Apr; 133(15):1472-83; discussion 1483. PubMed ID: 26969758
[TBL] [Abstract][Full Text] [Related]
4. Does endovascular treatment of infra-inguinal arterial disease with drug-eluting stents offer better results than angioplasty with or without bare metal stents?
Antoniou GA; Georgakarakos EI; Antoniou SA; Georgiadis GS
Interact Cardiovasc Thorac Surg; 2014 Aug; 19(2):282-5. PubMed ID: 24729201
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel Drug-Eluting Stents in Peripheral Arterial Disease: A Health Technology Assessment.
Health Quality Ontario
Ont Health Technol Assess Ser; 2015; 15(20):1-62. PubMed ID: 26719778
[TBL] [Abstract][Full Text] [Related]
6. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies.
Dake MD; Ansel GM; Jaff MR; Ohki T; Saxon RR; Smouse HB; Snyder SA; O'Leary EE; Tepe G; Scheinert D; Zeller T;
J Am Coll Cardiol; 2013 Jun; 61(24):2417-2427. PubMed ID: 23583245
[TBL] [Abstract][Full Text] [Related]
7. Two-year analysis of the Japanese cohort from the Zilver PTX randomized controlled trial supports the validity of multinational clinical trials.
Ohki T; Yokoi H; Kichikawa K; Kimura T; Snyder SA; Ragheb AO; O'Leary EE; Jaff MR; Ansel GM; Dake MD
J Endovasc Ther; 2014 Oct; 21(5):644-53. PubMed ID: 25290792
[TBL] [Abstract][Full Text] [Related]
8. Impact of Chronic Renal Failure on Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Artery Disease: Subgroup Analysis from Zilver PTX Post-Market Surveillance Study in Japan.
Ogawa Y; Yokoi H; Ohki T; Kichikawa K; Nakamura M; Komori K; Nanto S; O'Leary EE; Lottes AE; Saunders AT; Dake MD
Cardiovasc Intervent Radiol; 2017 Nov; 40(11):1669-1677. PubMed ID: 28488101
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of a paclitaxel-eluting stent (Eluvia) compared to Zilver PTX for endovascular femoropopliteal intervention.
Gray WA; Griffiths RI; Elroy PWM; Amorosi SL; McGovern AM; Jaff MR; Akehurst R; Müller-Hülsbeck S
J Med Econ; 2022; 25(1):880-887. PubMed ID: 35703041
[TBL] [Abstract][Full Text] [Related]
10. Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 12-Month Results.
Yokoi H; Ohki T; Kichikawa K; Nakamura M; Komori K; Nanto S; O'Leary EE; Lottes AE; Snyder SA; Dake MD
JACC Cardiovasc Interv; 2016 Feb; 9(3):271-277. PubMed ID: 26847118
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel-Coated Zilver PTX Drug-Eluting Stent Treatment Does Not Result in Increased Long-Term All-Cause Mortality Compared to Uncoated Devices.
Dake MD; Ansel GM; Bosiers M; Holden A; Iida O; Jaff MR; Lottes AE; O'Leary EE; Saunders AT; Schermerhorn M; Yokoi H; Zeller T
Cardiovasc Intervent Radiol; 2020 Jan; 43(1):8-19. PubMed ID: 31502026
[TBL] [Abstract][Full Text] [Related]
12. Polymer-based drug-eluting stent treatment extends the time to reintervention for patients with symptomatic femoropopliteal artery disease: clinical evidence and potential economic value.
Gray WA; Soga Y; Fujihara M; Iida O; Babaev A; Kawasaki D; Zeller T; O'Connor D; Jaff MR; Chavez AM; Müller-Hülsbeck S
J Comp Eff Res; 2024 Jun; 13(6):e240025. PubMed ID: 38606556
[No Abstract] [Full Text] [Related]
13. Zilver PTX Post-market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan: 2-Year Results.
Kichikawa K; Ichihashi S; Yokoi H; Ohki T; Nakamura M; Komori K; Nanto S; O'Leary EE; Lottes AE; Snyder SA; Dake MD
Cardiovasc Intervent Radiol; 2019 Mar; 42(3):358-364. PubMed ID: 30411151
[TBL] [Abstract][Full Text] [Related]
14. Drug delivering technology for endovascular management of infrainguinal peripheral artery disease.
Sarode K; Spelber DA; Bhatt DL; Mohammad A; Prasad A; Brilakis ES; Banerjee S
JACC Cardiovasc Interv; 2014 Aug; 7(8):827-39. PubMed ID: 25147028
[TBL] [Abstract][Full Text] [Related]
15. Update on PADI trial: percutaneous transluminal angioplasty and drug-eluting stents for infrapopliteal lesions in critical limb ischemia.
Martens JM; Knippenberg B; Vos JA; de Vries JP; Hansen BE; van Overhagen H;
J Vasc Surg; 2009 Sep; 50(3):687-9. PubMed ID: 19700099
[TBL] [Abstract][Full Text] [Related]
16. Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions.
Zeller T; Rastan A; Macharzina R; Tepe G; Kaspar M; Chavarria J; Beschorner U; Schwarzwälder U; Schwarz T; Noory E
J Endovasc Ther; 2014 Jun; 21(3):359-68. PubMed ID: 24915582
[TBL] [Abstract][Full Text] [Related]
17. Femoropopliteal in-stent restenosis: review and potential for drug based therapy.
Phillips J; Ansel G
J Cardiovasc Surg (Torino); 2013 Jun; 54(3):333-6. PubMed ID: 23640356
[TBL] [Abstract][Full Text] [Related]
18. A budget impact model for paclitaxel-eluting stent in femoropopliteal disease in France.
De Cock E; Sapoval M; Julia P; de Lissovoy G; Lopes S
Cardiovasc Intervent Radiol; 2013 Apr; 36(2):362-70. PubMed ID: 23073560
[TBL] [Abstract][Full Text] [Related]
19. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
[TBL] [Abstract][Full Text] [Related]
20. Drug-coated balloons to improve femoropopliteal artery patency: Rationale and design of the LEVANT 2 trial.
Jaff MR; Rosenfield K; Scheinert D; Rocha-Singh K; Benenati J; Nehler M; White CJ
Am Heart J; 2015 Apr; 169(4):479-85. PubMed ID: 25819854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
